Philippe Bulens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philippe Bulens has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
A. Debucquoy
6 shared publicationsK. Haustermans
6 shared publications- Christophe M. Deroose
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
5 shared publications - Karin Haustermans
Department of Oncology, KU Leuven, Leuven, Belgium; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
5 shared publications V. Vandecaveye
4 shared publicationsA. Wolthuis
3 shared publications
Latest Publications
- 24 July 2025
- Published by Springer Nature in Lasers in Medical Science
- Vol. 40 (1) , 1-12
Photobiomodulation therapy in the prevention of chemotherapy-induced alopecia in breast cancer patients: a randomized controlled trial
Purpose Chemotherapy-induced alopecia (CIA) is a prominent side effect of chemotherapy, negatively impacting the patient’s body image and self-confidence. Scalp cooling (SC) has emerged as a preventive option for CIA, but the success rate and adherence vary. Research shows that photobiomodulation (PBM) can improve hair growth by stimulating cell proliferation and repair processes. This trial aims to evaluate the effectiveness of PBM combined with SC in preventing CIA. Methods A randomized, controlled trial with 29 breast cancer patients undergoing taxane-based chemotherapy was performed at the Jessa Hospital (Belgium). Patients were randomized into the control (n = 16) or the intervention group (n = 13). Blinded researchers evaluated scalp coverage and hair thickness, while questionnaires were administered to assess scalp coverage, satisfaction, and health-related quality of life (HRQL). The trial was registered at clinicaltrials.gov (NCT05177289, 4th of January 2022). Results The scalp coverage and hair thickness did not differ significantly between the two groups. Patients in the PBM group scored higher on global health (P = 0.043), physical functioning (P = 0.039), role functioning (P = 0.049), and social functioning (P = 0.038). Patients receiving a paclitaxel-based chemotherapy showed less hair loss compared to patients undergoing a docetaxel-based regimen (Ps < 0.001). No differences in SC adherence could be observed between the two groups. Conclusions The addition of PBM to SC did not increase its efficacy in preventing hair loss during chemotherapy. Patients in the PBM group did score their HRQL higher compared to the control group. Further research is required to establish the use of PBM in CIA prevention and to corroborate these findings.
- 24 July 2025
- Published by Springer Nature in Lasers in Medical Science
- Vol. 40 (1) , 1-12
Photobiomodulation therapy in the prevention of chemotherapy-induced alopecia in breast cancer patients: a randomized controlled trial
Purpose Chemotherapy-induced alopecia (CIA) is a prominent side effect of chemotherapy, negatively impacting the patient’s body image and self-confidence. Scalp cooling (SC) has emerged as a preventive option for CIA, but the success rate and adherence vary. Research shows that photobiomodulation (PBM) can improve hair growth by stimulating cell proliferation and repair processes. This trial aims to evaluate the effectiveness of PBM combined with SC in preventing CIA. Methods A randomized, controlled trial with 29 breast cancer patients undergoing taxane-based chemotherapy was performed at the Jessa Hospital (Belgium). Patients were randomized into the control (n = 16) or the intervention group (n = 13). Blinded researchers evaluated scalp coverage and hair thickness, while questionnaires were administered to assess scalp coverage, satisfaction, and health-related quality of life (HRQL). The trial was registered at clinicaltrials.gov (NCT05177289, 4th of January 2022). Results The scalp coverage and hair thickness did not differ significantly between the two groups. Patients in the PBM group scored higher on global health (P = 0.043), physical functioning (P = 0.039), role functioning (P = 0.049), and social functioning (P = 0.038). Patients receiving a paclitaxel-based chemotherapy showed less hair loss compared to patients undergoing a docetaxel-based regimen (Ps < 0.001). No differences in SC adherence could be observed between the two groups. Conclusions The addition of PBM to SC did not increase its efficacy in preventing hair loss during chemotherapy. Patients in the PBM group did score their HRQL higher compared to the control group. Further research is required to establish the use of PBM in CIA prevention and to corroborate these findings.
- 11 October 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (11) , 1-12
A novel, multi-active emollient for the prevention of acute radiation dermatitis in breast cancer patients: a randomized clinical trial
Purpose To investigate the efficacy of a novel, multi-active emollient in preventing and managing acute radiation dermatitis (ARD) in breast cancer patients undergoing moderate hypofractionated (HF) radiotherapy (RT) compared to standard of care. Methodsa A monocentric, open-label, randomized clinical trial (RCT) with breast cancer patients receiving moderate HF (dose: 40.05–55.86 Gy, fractions: 15–21) was conducted between January 2022 and May 2023. The experimental group received the novel emollient, while the control group received the standard skin care. Patients applied the skin care products twice daily during the complete RT course. The primary outcome was the severity of ARD at the final RT session measured by the modified Radiation Therapy Oncology Group (RTOG) criteria. Secondary outcomes included patient symptoms, quality of life (QoL), and treatment satisfaction. Results A total of 100 patients with 50 patients per group were enrolled. In the control group, 50% of the patients developed RTOG grade 1 ARD and 48% grade 2 or higher, while in the experimental group, the severity of ARD was significantly lower with 82% grade 1 and 16% grade 2 ARD (P = .013, χ2-test). The frequency and severity of xerosis were significantly lower in the experimental compared to the control group (Ps ≤ .036, Mann Whiney U test). The impact of ARD on the QoL was low, and treatment satisfaction was high in both groups, with no significant difference. Conclusion This RCT shows that the novel, multi-active emollient significantly reduced the ARD RTOG grade. Research in a more diverse patient population is warranted. Trial registration ClinicalTrials.gov: NCT04929808 (11/06/2021).
- 11 October 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (11) , 1-12
A novel, multi-active emollient for the prevention of acute radiation dermatitis in breast cancer patients: a randomized clinical trial
Purpose To investigate the efficacy of a novel, multi-active emollient in preventing and managing acute radiation dermatitis (ARD) in breast cancer patients undergoing moderate hypofractionated (HF) radiotherapy (RT) compared to standard of care. Methodsa A monocentric, open-label, randomized clinical trial (RCT) with breast cancer patients receiving moderate HF (dose: 40.05–55.86 Gy, fractions: 15–21) was conducted between January 2022 and May 2023. The experimental group received the novel emollient, while the control group received the standard skin care. Patients applied the skin care products twice daily during the complete RT course. The primary outcome was the severity of ARD at the final RT session measured by the modified Radiation Therapy Oncology Group (RTOG) criteria. Secondary outcomes included patient symptoms, quality of life (QoL), and treatment satisfaction. Results A total of 100 patients with 50 patients per group were enrolled. In the control group, 50% of the patients developed RTOG grade 1 ARD and 48% grade 2 or higher, while in the experimental group, the severity of ARD was significantly lower with 82% grade 1 and 16% grade 2 ARD (P = .013, χ2-test). The frequency and severity of xerosis were significantly lower in the experimental compared to the control group (Ps ≤ .036, Mann Whiney U test). The impact of ARD on the QoL was low, and treatment satisfaction was high in both groups, with no significant difference. Conclusion This RCT shows that the novel, multi-active emollient significantly reduced the ARD RTOG grade. Research in a more diverse patient population is warranted. Trial registration ClinicalTrials.gov: NCT04929808 (11/06/2021).
- Open Access
- 26 July 2022
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 36, 113-120
Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study
- 26 July 2022
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 36, 113-120
Open AccessNonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study
- 1 January 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 142, 246-252
Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics
- 1 January 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 142, 246-252
Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , S105
Patient-Reported Functional Outcome of Patients with Rectal Cancer Undergoing Watch-and-Wait vs. Surgery after Chemoradiotherapy
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , S105
Patient-Reported Functional Outcome of Patients with Rectal Cancer Undergoing Watch-and-Wait vs. Surgery after Chemoradiotherapy
- Open Access
- 2 July 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , iv120
Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait
Introduction: Organ-preserving strategies after chemoradiotherapy for rectal cancer are becoming more appealing. In the case of early regrowth, salvage surgery should be undertaken. In this analysis, we evaluate the surgical outcome and preliminary survival outcome of patients that underwent upfront surgery due to non-complete response to chemoradiotherapy versus patients that underwent salvage surgery for a local regrowth after watch-and-wait (W&W).
- 2 July 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , iv120
Open AccessComparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait
Introduction: Organ-preserving strategies after chemoradiotherapy for rectal cancer are becoming more appealing. In the case of early regrowth, salvage surgery should be undertaken. In this analysis, we evaluate the surgical outcome and preliminary survival outcome of patients that underwent upfront surgery due to non-complete response to chemoradiotherapy versus patients that underwent salvage surgery for a local regrowth after watch-and-wait (W&W).
- Open Access
- 1 April 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 133, S265-S266
OC-0510 MRI radiomics to predict tumour response in patients with locally advanced rectal cancer
- 1 April 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 133, S265-S266
Open AccessOC-0510 MRI radiomics to predict tumour response in patients with locally advanced rectal cancer
- 1 November 2018
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 62 (4) , 385-403
PET imaging in adaptive radiotherapy of gastrointestinal tumors
Radiotherapy is a cornerstone in the multimodality treatment of several gastrointestinal (GI) tumors. Positron-emission tomography (PET) has an established role in the diagnosis, response assessment and (re-)staging of these tumors. Nevertheless, the value of PET in adaptive radiotherapy remains unclear. This review focuses on the role of PET in adaptive radiotherapy, i.e. during the treatment course and in the delineation process. The MEDLINE database was searched for the terms ("Radiotherapy"[Mesh] AND "Positron-Emission Tomography"[Mesh] AND one of the site-specific keywords, yielding a total of 1710 articles. After abstract selection, 27 papers were identified for esophageal neoplasms, 1 for gastric neoplasms, 9 for pancreatic neoplasms, 6 for liver neoplasms, 1 for biliary tract neoplasms, none for colonic neoplasms, 15 for rectal neoplasms and 12 for anus neoplasms. The use of PET for truly adaptive radiotherapy during treatment for GI tumors has barely been investigated, in contrast to the potential of the PET-defined metabolic tumor volume for optimization of the target volume. The optimized target definition seems useful for treatment individualization such as focal boosting strategies in esophageal, pancreatic and anorectal cancer. Nevertheless, for all GI tumors, further investigation is needed. In general, too little data are available to conclude on the role of PET imaging during radiotherapy for ART strategies in GI cancer. On the other hand, based on the available evidence, the use of biological imaging for target volume adaptation seems promising and could pave the road towards individualized treatment strategies.
- 1 November 2018
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 62 (4) , 385-403
PET imaging in adaptive radiotherapy of gastrointestinal tumors
Radiotherapy is a cornerstone in the multimodality treatment of several gastrointestinal (GI) tumors. Positron-emission tomography (PET) has an established role in the diagnosis, response assessment and (re-)staging of these tumors. Nevertheless, the value of PET in adaptive radiotherapy remains unclear. This review focuses on the role of PET in adaptive radiotherapy, i.e. during the treatment course and in the delineation process. The MEDLINE database was searched for the terms ("Radiotherapy"[Mesh] AND "Positron-Emission Tomography"[Mesh] AND one of the site-specific keywords, yielding a total of 1710 articles. After abstract selection, 27 papers were identified for esophageal neoplasms, 1 for gastric neoplasms, 9 for pancreatic neoplasms, 6 for liver neoplasms, 1 for biliary tract neoplasms, none for colonic neoplasms, 15 for rectal neoplasms and 12 for anus neoplasms. The use of PET for truly adaptive radiotherapy during treatment for GI tumors has barely been investigated, in contrast to the potential of the PET-defined metabolic tumor volume for optimization of the target volume. The optimized target definition seems useful for treatment individualization such as focal boosting strategies in esophageal, pancreatic and anorectal cancer. Nevertheless, for all GI tumors, further investigation is needed. In general, too little data are available to conclude on the role of PET imaging during radiotherapy for ART strategies in GI cancer. On the other hand, based on the available evidence, the use of biological imaging for target volume adaptation seems promising and could pave the road towards individualized treatment strategies.
- Open Access
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S1273-S1274
EP-2308: Inhibition of lipogenesis: a promising approach to optimise the treatment of rectal cancer
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S1273-S1274
Open AccessEP-2308: Inhibition of lipogenesis: a promising approach to optimise the treatment of rectal cancer
- 1 March 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 126 (3) , 437-442
Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer
- 1 March 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 126 (3) , 437-442
Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer